NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

RecruitingN/A

Sponsor: City of Hope Medical Center

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Small RNA sequencing, PRECEPT assay (qRT-PCR validation)

Countries: United States

This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
* Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
* Availability of pre-treatment plasma samples.
* Underwent curative-intent resection (R0 or R1).

Exclusion Criteria:

* Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
* Non-adenocarcinoma histology.
* Presence of synchronous or multiple primary malignancies.
* Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
* Presence of active inflammatory or autoimmune diseases.

Locations (1)

Duarte, California, United States